论文部分内容阅读
目的 观察CD19和CD20在急性白血病 (AL)细胞中的表达与分布 ,为免疫毒素导向治疗药物的合理应用提供依据。方法 采用27个直接荧光素标记的单克隆抗体 (单抗 )及CD45/SSC双参数设门多色流式细胞术对321例AL患者白血病细胞进行免疫学诊断和分型 ,并对CD19和CD20在各种类型AL细胞中的表达情况进行分析。 结果 在116例B系ALL患者中 ,CD19持续稳定表达 ,其阳性率(99.1%)高于CD20阳性率(28.4%,P=0.001) ;在17例具B系特征的杂合型白血病 (HAL)细胞中 ,CD19阳性率也明显高于CD20(P<0.01) ,而在29例T细胞系ALL和7例T/MyHAL细胞中 ,两者均无表达。在152例急性髓系白血病(AML)细胞中 ,CD19和CD20阳性率均很低 ,分别为7.2%和2.0%。 结论 CD19在B细胞系细胞的各分化阶段上持续稳定表达 ,且反应谱比CD20宽 ,CD19免疫毒素可能成为治疗大多数B系ALL的最佳选择。
Objective To observe the expression and distribution of CD19 and CD20 in acute leukemia (AL) cells and provide the basis for the rational application of immunotoxin-directed therapies. Methods Thirty-seven cases of AL patients with leukemia were immunologically diagnosed and classified by 27 direct fluorescein-labeled monoclonal antibodies (McAbs) and CD45 / SSC double-parameter multiplex gate flow cytometry. CD19 and CD20 The expression in various types of AL cells was analyzed. Results The positive rate of CD19 was higher than that of CD20 (28.4%, P = 0.001) in 116 B-line ALL patients. The positive rate of CD19 in 17 cases with heterozygous B-lineage heterozygous leukemia ) Cells, the positive rate of CD19 was also significantly higher than that of CD20 (P <0.01), but not in 29 T cell line ALL and 7 T / MyHAL cells. In 152 cases of acute myeloid leukemia (AML) cells, the positive rates of CD19 and CD20 were very low, which were 7.2% and 2.0% respectively. CONCLUSIONS: CD19 is stably expressed at all stages of B cell lineage and its response spectrum is broader than that of CD20. CD19 immunotoxin may be the best choice for the treatment of most B-lineage ALL.